Cart
sales@molnova.com
Tenofovir amibufenamide
CAS No. 1571076-26-0
Tenofovir amibufenamide( —— )
Catalog No. M35088 CAS No. 1571076-26-0
Tenofovir amibufenamide (HS-10234) is a Tenofovir prodrug, an antiviral compound with oral activity. Tenofovir amibufenamide inhibits hepatitis B virus (HBV) and can be used in chronic hepatitis B (CHB) studies.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 354 | Get Quote |
|
| 5MG | 550 | Get Quote |
|
| 10MG | 825 | Get Quote |
|
| 25MG | 1279 | Get Quote |
|
| 50MG | 1776 | Get Quote |
|
| 100MG | 2385 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameTenofovir amibufenamide
-
NoteResearch use only, not for human use.
-
Brief DescriptionTenofovir amibufenamide (HS-10234) is a Tenofovir prodrug, an antiviral compound with oral activity. Tenofovir amibufenamide inhibits hepatitis B virus (HBV) and can be used in chronic hepatitis B (CHB) studies.
-
DescriptionTenofovir amibufenamide (HS-10234), a Tenofovir prodrug, is an orally active antiviral agent. Tenofovir amibufenamide inhibits HBV, and can be used for chronic hepatitis B (CHB) study.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMicrobiology/Virology
-
TargetHBV
-
RecptorHBV
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1571076-26-0
-
Formula Weight490.49
-
Molecular FormulaC22H31N6O5P
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 200 mg/mL (407.76 mM; Ultrasonic )
-
SMILESC([C@H](OCP(OC1=CC=CC=C1)(NC(C(OC(C)C)=O)(C)C)=O)C)N2C=3C(N=C2)=C(N)N=CN3
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Zhihong Liu, et al. Randomised clinical trial: 48 weeks of treatment with tenofovir amibufenamide versus tenofovir disoproxil fumarate for patients with chronic hepatitis B. Aliment Pharmacol Ther. 2021 Nov;54(9):1134-1149.?
molnova catalog
related products
-
RO6889678
RO6889678 is a highly potent inhibitor of HBV capsid formation with attributes that are favorable for targeting the liver, whilst maintaining moderate peripheral exposure.
-
NTCP binder peptide ...
NTCP binder peptide WL4 is a macrocyclic peptide, pan-genotypic inhibitor of HBV cellular entry via targeting the cell-surface receptor for HBV.
-
JNJ-632
JNJ-632 (JNJ632) is a novel potent HVV capsid assembly modulator and HBV replication inhibitor.
